NCT01084889

Brief Summary

The purpose of this study is to determine the influence of Anterior Pelvic Prolapse Reconstruction with a titanised polypropylene mesh on rate of erosion and patients quality of live.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
292

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2010

Longer than P75 for all trials

Geographic Reach
1 country

9 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 10, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 11, 2010

Completed
21 days until next milestone

Study Start

First participant enrolled

April 1, 2010

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2014

Completed
2.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

February 4, 2019

Status Verified

January 1, 2019

Enrollment Period

3.8 years

First QC Date

March 10, 2010

Last Update Submit

January 31, 2019

Conditions

Keywords

polypropylene meshProlapseCystoceleSurgical Mesh

Outcome Measures

Primary Outcomes (2)

  • Erosion rate

    Erosion, in the sense of the end point, is any erosion requiring more than simply the cut off of a single short filament.

    12 months

  • Patient's quality of life

    It will be shown that by means of a validated questionnaire whether the subjective quality of life after 6 months is significantly better than before implantation.

    6 months

Secondary Outcomes (4)

  • Adverse Events

    at 6, 12, 36 months

  • Feasibility of the mesh implantation

    6 months

  • Erosion rate

    36 months

  • Patient's quality of life

    12 and 36 months

Study Arms (1)

symptomatic genital descensus

Women with a symptomatic genital descensus : at least stage II (ICS-classification according pelvic organ prolapse quanification (POP-Q) system), or stage I with a symptomatic requiring intervention. Standard method to implant the TiLOOP® Total 6 surgical mesh transvaginally.

Device: surgical mesh implantation (TiLOOP® Total 6)

Interventions

The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The surgical mesh TiLOOP® Total 6 is placed transvaginal by the aid of TiLOOP® surgical instruments to place the mesh arms.

Also known as: TiLOOP® Total 6
symptomatic genital descensus

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women with a symptomatic genital descensus treated in the center

You may qualify if:

  • Women with a symptomatic genital descensus : at least stage II (ICS-classification according POP-Q system), or stage I with a symptomatic requiring intervention. This applies to primary as well as recurrent intervention
  • Existence of a cystocele.
  • Patient is mentally able to understand the nature, aims, or possible consequences of the clinical investigation
  • Patient information has been handed out and all written consents are at hand.
  • Patient has attained full age.

You may not qualify if:

  • Pregnancy or unfinished family planning.
  • Known intolerance to the mesh-implants under investigation.
  • Patients with acute (last 12 months) carcinoma.
  • Patients with history of radiotherapy in the pelvic area.
  • Genital descensus without any complaints.
  • Patients with implanted pelvic floor mesh.
  • Systemic steroid treatment.
  • Lack of written patients' informed consent.
  • Lack of patient compliance regarding data collection, treatment or follow-up investigations in the scope of the protocol.
  • Patient is institutionalised by court or official order (MPG §20.3).
  • Participation in another clinical investigation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Berliner Kontinenzzentrum am Franziskus Krankenhaus,

Berlin, 10787, Germany

Location

Krankenhaus Dresden- Friedrichsstadt

Dresden, 01067, Germany

Location

Evangelisches Diakoniekrankenhaus Freiburg

Freiburg im Breisgau, Germany

Location

Universitätsklinikum Eppendorf

Hamburg, 20246, Germany

Location

St. Elisabeth Krankenhaus Leipzig,

Leipzig, 04277, Germany

Location

Regionale Kliniken Holding RKH GmbH, Klinikum Ludwigsburg

Ludwigsburg, 71640, Germany

Location

Beckenbodenzentrum München

München, 81679, Germany

Location

Klinik Tettnang GmbH

Tettnang, 88069, Germany

Location

Klinikum Oberlausitzer Bergland gGmbH,

Zittau, 02763, Germany

Location

Related Publications (2)

  • Farthmann J, Mengel M, Henne B, Grebe M, Watermann D, Kaufhold J, Stehle M, Fuenfgeld C. Improvement of pelvic floor-related quality of life and sexual function after vaginal mesh implantation for cystocele: primary endpoint of a prospective multicentre trial. Arch Gynecol Obstet. 2016 Jul;294(1):115-21. doi: 10.1007/s00404-016-4014-0. Epub 2016 Jan 18.

  • Funfgeld C, Stehle M, Henne B, Kaufhold J, Watermann D, Grebe M, Mengel M. Quality of Life, Sexuality, Anatomical Results and Side-effects of Implantation of an Alloplastic Mesh for Cystocele Correction at Follow-up after 36 Months. Geburtshilfe Frauenheilkd. 2017 Sep;77(9):993-1001. doi: 10.1055/s-0043-116857. Epub 2017 Sep 25.

Related Links

MeSH Terms

Conditions

CystoceleUterine ProlapseProlapse

Condition Hierarchy (Ancestors)

Urinary Bladder DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesPelvic Organ ProlapsePathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsUterine DiseasesGenital Diseases, FemaleGenital Diseases

Study Officials

  • Christian Fünfgeld, Dr. MD

    Klinik Tettnang GmbH, Tettnang

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 10, 2010

First Posted

March 11, 2010

Study Start

April 1, 2010

Primary Completion

January 1, 2014

Study Completion

June 1, 2016

Last Updated

February 4, 2019

Record last verified: 2019-01

Data Sharing

IPD Sharing
Will not share

Locations